Whole Versus Partial Gland Boost During Prostate SBRT

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.
Epistemonikos ID: 4ea20131c1da983850f1ad21e372779fd74e03f0
First added on: May 09, 2026